Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib.

Blood Adv · 2026 · PMC13285838 · PMID 42048573

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Levels of ICAM-1 were also reduced by 38.4%, but the differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.